Information Provided By:
Fly News Breaks for January 2, 2018
IART
Jan 2, 2018 | 08:43 EDT
As previously reported, BofA/Merrill downgraded Integra LifeSciences to Neutral from Buy and raised its price target to $53 from $52. Analyst Bob Hopkins sees limited earnings upside in 2018, slightly higher risk from transition and integration, and better risk adjusted returns elsewhere.
News For IART From the Last 2 Days
There are no results for your query IART